Guggenheim initiated coverage on Novavax (NASDAQ: NVAX) with a Buy rating and a price target of $11.00.

For an analyst ratings summary and ratings history on Novavax click here. For more ratings news on Novavax click here.

Shares of Novavax closed at $8.86 yesterday.